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Aims Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is characterized by ventricular arrhythmias
(VAs) and sudden cardiac death (SCD). We aimed to develop a model for individualized prediction of incident VA/
SCD in ARVC patients.
...................................................................................................................................................................................................
Methods
and results
Five hundred and twenty-eight patients with a definite diagnosis and no history of sustained VAs/SCD at baseline,
aged 38.2 ± 15.5 years, 44.7% male, were enrolled from five registries in North America and Europe. Over 4.83
(interquartile range 2.44–9.33) years of follow-up, 146 (27.7%) experienced sustained VA, defined as SCD, aborted
SCD, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator (ICD) therapy. A
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prediction model estimating annual VA risk was developed using Cox regression with internal validation. Eight po-
tential predictors were pre-specified: age, sex, cardiac syncope in the prior 6 months, non-sustained ventricular
tachycardia, number of premature ventricular complexes in 24 h, number of leads with T-wave inversion, and right
and left ventricular ejection fractions (LVEFs). All except LVEF were retained in the final model. The model accur-
ately distinguished patients with and without events, with an optimism-corrected C-index of 0.77 [95% confidence
interval (CI) 0.73–0.81] and minimal over-optimism [calibration slope of 0.93 (95% CI 0.92–0.95)]. By decision
curve analysis, the clinical benefit of the model was superior to a current consensus-based ICD placement algo-
rithm with a 20.6% reduction of ICD placements with the same proportion of protected patients (P< 0.001).
...................................................................................................................................................................................................
Conclusion Using the largest cohort of patients with ARVC and no prior VA, a prediction model using readily available
clinical parameters was devised to estimate VA risk and guide decisions regarding primary prevention ICDs
(www.arvcrisk.com).
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Introduction
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC)
is an inherited cardiomyopathy characterized by progressive fibro-
fatty replacement of the myocardium which predisposes patients to
ventricular arrhythmias (VAs) and sudden cardiac death (SCD).
Once the diagnosis is established, a primary goal of management is
prevention of SCD, for which implantable cardioverter-defibrillators
(ICDs) are a common consideration. There is agreement that most
ARVC patients with a prior history of sustained VA or resuscitated
sudden cardiac arrest (SCA) benefit from secondary prevention
ICDs.1 However, for the primary prevention population, there is no
established risk stratification scheme.
Over the past two decades, multiple attempts have been made to
identify factors associated with VA in this clinically challenging popula-
tion.2–4 While these studies have significantly contributed to our
understanding of clinical, demographic, and behavioural factors asso-
ciated with arrhythmic risk, the relatively small patient populations
provided insufficient statistical power to assess the independent pre-
dictive value of potentially correlated risk factors.5
To overcome this important limitation, we assembled a large co-
hort of patients with ARVC from five registries (Johns Hopkins,
Dutch, Nordic, Swiss, and Canadian) without a history of sustained
VAs at baseline. Our aim was (i) to develop a model for individualized
prediction of incident sustained VA in patients with ARVC using read-
ily available clinical variables; and (ii) to compare this new model to a
current consensus-based ICD placement algorithm.
Methods
Study design
We conducted an observational, retrospective, longitudinal cohort study
in accordance with the Transparent Reporting of a Multivariable Prediction
Model for Individual Prognosis or Diagnosis (TRIPOD) statement.6
Study population
The study population was drawn from five ARVC registries encompassing
14 academic centres (Supplementary material online, Table S1) in six
countries. Each registry is itself a longitudinal cohort study. From each
registry, we included all patients who (i) were diagnosed with definite
ARVC by the current 2010 Task Force Criteria (TFC)7 and (ii) had not
experienced spontaneous sustained VA or SCA at diagnosis. The study
conforms to the Helsinki declaration and was approved by local ethics
and/or institutional review boards.
Study outcomes
The primary study outcome was the first sustained VA following diagnosis
by the TFC. Sustained VA was defined as a composite of the occurrence
of SCD, SCA, spontaneous sustained ventricular tachycardia (VT) (VT
lasting >_30 s at >_100 b.p.m. or with haemodynamic compromise requir-
ing cardioversion), ventricular fibrillation/flutter (VF), or appropriate ICD
intervention. The first episode of a rapid sustained VA (defined as SCD,
SCA, VF, or VT >250 b.p.m.), heart transplantation, cardiovascular mor-
tality, and all-cause mortality were also recorded.
Predictors
Potential predictors were pre-specified based on clinical experience and
current literature on arrhythmic risk stratification in ARVC including: (i) a
recent systematic review and meta-analysis5 and (ii) the International
Task Force Consensus (ITFC) Statement for Treatment of ARVD/C1 and
a recent analysis of the performance of its risk stratification algorithm.8
Variables considered were sex, age, recent (<6 months) cardiac syncope,
non-sustained VT (NSVT), number of premature ventricular complexes
(PVCs) on 24-h Holter monitoring, extent of T-wave inversion (TWI) on
anterior and inferior leads, right ventricular ejection fraction (RVEF), and
left ventricular ejection fraction (LVEF). Each predictor variable was
determined at the time of diagnosis, defined as 1 year before to 1 year
after the date of diagnosis by TFC but always prior to occurrence of the
primary outcome. Definitions of predictor variables are provided in
Supplementary material online, Table S2. In Supplementary material on-
line, Table S3, we describe the rationale for selecting each predictor, as
well as the rationale for excluding other variables.
Data collection
Data were collected independently by each registry according to stand-
ard operating procedures (Supplementary material online, Table S4).
Outcomes were adjudicated at each centre via review of electrocardio-
gram (ECG) tracings, ICD interrogation tracings, as well as medical and
death records. ECGs were interpreted through an ECG core laboratory
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by two cardiologists–electrophysiologists (J.C.T. and R.T.) blinded to the
rest of the data and outcomes. Genetic variants were adjudicated accord-
ing to the American College of Medical Genetics and Genomics guide-
lines by consensus of specialists in cardiac genetics (B.M., J.D.H.J., J.P.v.T.,
and C.A.J.).9
Statistical analysis
Analyses were performed using SAS software version 9.4 (SAS Institute,
Cary, NC, USA) and RStudio version 1.1.414 (Boston, MA, USA).
Categorical variables were summarized as frequencies (%) and compared
using the v2 or the Fisher’s exact tests, as appropriate. Continuous varia-
bles were presented as mean ± standard deviation or median [interquar-
tile range (IQR)], and compared using the independent sample t-test or
the Mann–Whitney U test. Follow-up duration was calculated from the
date of diagnosis to the date of reaching the endpoint or censoring, which
was defined as death from any other cause, heart transplantation, or the
most recent follow-up visit at which the endpoint could be ascertained.
The overall probability of survival free from sustained VA was estimated
using the Kaplan–Meier method.
Missing data
Potential bias from missing data was evaluated by comparing characteris-
tics of patients with one or more missing predictor variables to patients
with complete data. Missing quantitative values for RVEF and LVEF were
imputed manually when qualitative assessment was present (as detailed in
Supplementary material online, Table S4). Other missing data were
assumed to be missing at random and imputed using multiple imputation
with chained equations.10 The multiple imputation model included all
pre-specified predictors as well as proband status, QRS duration, right
ventricular volume, ICD carrier status, together with the outcome, and a
cumulative baseline hazard estimation.11 A total of 25 imputed datasets
were generated, and the final inference estimations were combined using
Rubin’s rules.12 A complete case analysis and an analysis without manual
imputation of RVEF and LVEF were conducted as sensitivity analyses.
Model development and validation
The association between the pre-specified predictors and the primary
outcome was assessed using Cox regression. Proportional-hazard
assumptions were verified as well as linearity of the association for con-
tinuous predictors. The final model was fitted using stepwise backward
selection based on Akaike’s Information Criterion.6 The discriminative
performance of the model was measured using Harrell’s C-statistic.
The model was validated using 200 bootstrap samples. The degree of
optimism was estimated by the average calibration slope of the bootstrap
samples.13 Agreement between predicted and observed outcomes was
evaluated graphically using calibration plots that incorporated grouped
Kaplan–Meier estimates and the continuous hazard regression function.14
Calibration analyses were repeated for patient subgroups including geno-
type and ICD status.
Model presentation
For an individual patient, the risk of sustained VA was calculated using the
following equation:
PðVA at time tÞ= 1-S0ðtÞ exp ðLPÞ
where S0(t) is the baseline survival probability at time t (i.e. at 5 years),
and LP (linear predictor) is the sum of the products of the predictors and
associated coefficients for a given patient.
Clinical utility
To assess the implications of our model in clinical practice, we compared
performance of our model to that of the consensus-based algorithm for
ICD placement published in the ITFC Statement for Treatment of
ARVC.1 First, we explored the clinical impact of potential thresholds for
ICD implantation by evaluating the proportions of appropriate and in-
appropriate treatment at each of these thresholds. Second, we per-
formed a decision curve analysis to evaluate the clinical benefit of our
model. In this analysis, the clinical benefit was assessed by the ‘net benefit’;
a weighted measure of the balance between appropriate and inappropri-
ate ICD implantations.15 A value of 0 indicates no benefit, while higher
values indicate greater benefit.
Results
Study population
The study population consisted of 528 patients with definite ARVC
and no history of sustained VA or SCA at time of diagnosis. Almost
half (n= 236, 44.7%) of the population was male with an average age
at diagnosis of 38.2± 15.5 years. Probands (n= 263, 49.8%), the first
affected individual in a family seeking medical attention for ARVC,
and family members (n= 265, 50.2%) were equally represented.
Two-thirds (n= 340, 64.4%) of patients had a pathogenic or likely
pathogenic variant (e.g. mutation) in an ARVC-associated gene.
Other clinical and demographic characteristics are summarized in
Table 1. The study population had balanced representation from
North America (n= 259, 49.1%) and Europe (n= 269, 50.9%).
Characteristics of patients contributed by each registry are shown in
Supplementary material online, Table S5.
Overall, 390 (73.8%) patients had complete data for the pre-
specified predictors. Missing data occurred for six of the eight predic-
tors: recent cardiac syncope (n= 9, 1.7%), NSVT (n= 58, 11.0%),
PVC count (n= 103, 19.5%), sum of TWI in anterior and inferior
leads (n= 22, 4.2%), RVEF (n= 19, 3.6%), and LVEF (n= 13, 2.5%).
Outcomes
During a median follow-up of 4.83 years (IQR 2.44–9.33 years), 146
(27.7%) patients experienced the composite outcome, with a corre-
sponding annual event rate of 5.6% [95% confidence interval (CI)
4.7–6.6]. Figure 1 shows the cumulative survival free from first sus-
tained VA. As shown in the figure, events occurred throughout
follow-up, with a cumulative event-free survival at 5 years of 73.6%
(95% CI 69.4–78.0%). The most common first sustained VA was ap-
propriate ICD therapy (n= 102, 70.0%), followed by spontaneous
sustained VT (n= 35, 23.9%), SCA (n= 6, 4.1%), and SCD (n= 3,
2.0%). Rapid sustained VAs (VT with cycle length <240 ms, SCA, or
SCD) were experienced by 53 (10.0%) patients during follow-up at
an annual event rate of 1.7% (95% CI 1.3–2.2). At last follow-up, 18
(3.4%) patients had died and 14 (2.7%) had undergone heart
transplantation.
Model development
Table 1 shows baseline characteristics of patients with and without
sustained VA during follow-up. Table 2 summarizes development of
the risk prediction model. As shown in these tables, each pre-
specified predictor had a significant (P< 0.05) univariable linear or
1852 J. Cadrin-Tourigny et al.
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were, therefore, fitted into a multivariable model, after which step-
wise backward selection was performed leading to the removal of
LVEF from the final model. As a sensitivity analysis, we repeated this
process (i) for patients with complete data and (ii) without manual
imputation for RVEF. As can be appreciated from Supplementary ma-
terial online, Table S6, this resulted in inclusion of the same predictor
variables (i.e. excluding LVEF) with only small changes to the coeffi-
cients in the resulting model.
The following formula allows for the calculation of the 5-year risk
of sustained VA:
PðVA at 5 yearsÞ = 1-0:801 exp ðLPÞ
where LP = 0.488*sex - 0.022*age þ 0.657*history of recent cardiac
syncope þ 0.811*history of NSVT þ 0.170*ln(24 h PVC count) þ
0.113*Sum of anterior and inferior leads with TWI - 0.025*RVEF.
Supplementary material online, Table S7 provides the probability
of survival (S0(t)) at 1, 2, 3, and 4 years to facilitate calculating risk for
shorter time durations.
Supplementary material online, Table S8 illustrates the use
of this risk calculator in 3 patients from our cohort. An online
application to calculate risk for an individual patient is available at:
www.arvcrisk.com.
Model validation
The optimism-corrected C-statistic of the predictive model was 0.77
(95% CI 0.73–0.81). Internal validation with bootstrapping revealed a
calibration slope of 0.93 (95% CI 0.92–0.95), reflecting a small degree
of over-optimism. Figure 2 presents a graphical representation of cali-
bration, showing good overall agreement between the predicted and
observed 5-year risk. Calibration plots showing similarly good agree-
ment for shorter follow-up durations can be found in Supplementary
....................................................................................................................................................................................................................
Table 1 Baseline clinical characteristics
Overall Patients without
sustained VA
Patients with
sustained VA
P-value
Total 528 (100.0) 382 (72.3) 146 (27.7)
Demographics
Male sex 236 (44.7) 155 (40.6) 81 (55.5) 0.003
Age at diagnosis (years) 38.16 ± 15.47 39.73 ± 15.84 34.05 ± 13.67 <0.001
Caucasian ethnicity (n = 498) 485 (91.9) 348 (91.1) 137 (93.8) 0.064
Proband status 263 (49.8) 151 (39.5) 112 (76.7) <0.001
Pathogenic mutation (n = 504) 340 (64.4) 248 (64.9) 92 (63.0) 0.599
PKP2 258 (48.9) 185 (48.4) 73 (50.0) 0.582
DSP 23 (4.4) 18 (4.7) 5 (3.4)
DSG2 17 (3.2) 15 (3.9) 2 (1.4)
PLN 26 (4.9) 19 (5.0) 7 (4.8)
Multiple mutations 6 (1.1) 4 (1.0) 2 (1.4)
Other 10 (1.9) 7 (1.8) 3 (2.1)
History
Symptoms 307 (58.1) 190 (49.7) 117 (80.1) <0.001
Cardiac syncope 107 (20.3) 59 (15.4) 48 (32.9) <0.001
Recent cardiac syncope (n = 519) 48 (9.1) 23 (6.0) 25 (17.1) <0.001
ECG/continuous ECG monitoring
TWI in >_3 precordial leads (n = 517) 298 (56.4) 193 (50.5) 105 (71.9) <0.001
TWI in >_2 inferior leads (n = 506) 85 (16.1) 53 (13.9) 32 (21.9) 0.021
NSVT (n = 470) 231 (43.8) 145 (38.0) 86 (58.9) <0.001
24 h PVC count (n = 425) 1007 (278–3731) 833 (125–2768) 2782 (992–5918) <0.001
Imaging
RVEF (%) (n = 510)a 43.80 ± 10.40 45.40 ± 9.55 39.33 ± 11.37 <0.001
LVEF (%) (n = 515) 57.66 ± 8.42 58.16 ± 8.00 56.34 ± 9.34 0.029
Treatment at baseline
ICD 218 (41.3) 136 (35.6) 82 (56.2) <0.001
Beta-blockers (n = 511) 200 (37.9) 142 (37.2) 58 (39.7) 0.343
Anti-arrhythmic drugs (n = 510) 82 (15.5) 50 (13.1) 32 (21.9) 0.019
Variables are expressed as frequency (%), mean ± standard deviation, or median (IQR). Total number of patients for a given variable mentioned if missing data.
DSG2, desmoglein-2; DSP, desmoplakin; ICD, implantable cardioverter-defibrillator; IQR, interquartile range; LVEF, left ventricular ejection fraction; NSVT, non-sustained ven-
tricular tachycardia; PKP2, plakophilin-2; PLN, phospholamban; PVC, premature ventricular complex; RVEF, right ventricular ejection fraction; TWI, T-wave inversion; VA, ven-
tricular arrhythmia.
aRVEF estimation was based on quantitative measurement by CMR in 327 patients, by echocardiography in 160, by qualitative CMR assessment in 20, and by angiography in 3.
ARVC VA prediction model 1853
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material online, Figure S1. Additional calibration plots for patients
stratified by ICD carrier status and genotype are presented in
Supplementary material online, Figure S2. As can be appreciated from
this figure, predicted and observed 5-year risk remained concordant
in these patient subgroups.
Clinical utility
To assess the implications of our model in clinical practice, we
explored the impact of potential 5-year VA risk thresholds for ICD
implantation in our model vs. the ITFC consensus algorithm (i.e. ICD
implantation in those with an ITFC Class I/IIa indication).1 This is laid
out in Figure 3. As can be appreciated from the two last columns of
Supplementary material online, Table S9, applying the ITFC algorithm
would have resulted in treating 355 (67.2%) patients and protecting
131 (89.9%) of those who subsequently developed VA. In compari-
son, to provide the same level of protection (89.9%), our model
would result in the implantation of 282 (53.4%) ICDs, thereby reduc-
ing the total number of ICD implants by 20.6% [(355–282)/355]
(P< 0.001).
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Figure 1 Cumulative survival free from sustained ventricular ar-
rhythmia. Plotted is the cumulative event-free survival for any ven-
tricular arrhythmia with 95% confidence intervals (shaded area).
Dotted line represents cumulative 5-year survival.
....................................................... ...............................................................
....................................................................................................................................................................................................................
Table 2 Ventricular arrhythmia risk prediction model
Univariable model Multivariable (final model)
HR (95% CI) P-value HR (95% CI) P-value
Male sex 1.74 (1.26–2.42) <0.001 1.63 (1.17–2.29) 0.005
Age (per year increase) 0.98 (0.97–0.99) 0.001 0.98 (0.97–0.99) <0.001
Recent cardiac syncope 2.57 (1.66–3.97) <0.001 1.93 (1.20–3.11) 0.007
Prior NSVT 3.15 (2.12–4.68) <0.001 2.25 (1.47–3.44) <0.001
24 h PVC count (ln)a 1.32 (1.17–1.48) <0.001 1.19 (1.05–1.34) 0.013
Leads with TWI anterior þ inferior 1.20 (1.12–1.29) <0.001 1.12 (1.02–1.23) 0.014
RVEF (per % decrease) 1.05 (1.03–1.06) <0.001 1.03 (1.01–1.04) 0.002
LVEF (per % decrease) 1.02 (1.01–1.04) 0.011 Not included in the final model
LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular tachycardia; PVC, premature ventricular complex; RVEF, right ventricular ejection fraction; TWI, T-
wave inversion.
aPVC count had a log-linear relationship.
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Total (n)    = 528
VA (n)    = 146
Avg. group size (n) = 106
Figure 2 Calibration plot showing the agreement between pre-
dicted (x axis) and observed (y axis) 5-year risk of the primary out-
come. Triangles represent binned Kaplan–Meier estimates with 95%
confidence intervals for quintiles of predicted risk. Straight line is the
continuous calibration hazard regression. Dotted line represents
perfect calibration. Spike histogram on the x axis reflects the num-
ber of patients with a predicted risk corresponding to the x axis
value. VA, ventricular arrhythmia.
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We subsequently compared the clinical performance of our model
to the ITFC algorithm using decision curve analysis. As shown in
Figure 4, our proposed model was associated with the highest net
benefit within the entire range of potential treatment thresholds for
ICD placement. This suggests superiority in clinical practice regard-
less of implantation threshold.
Discussion
Main findings
We developed and internally validated the first prediction model to
generate individualized risk estimates for sustained VA in patients
with ARVC. This model accurately distinguished patients who had in-
cident sustained VA during follow-up from those who did not using
seven non-invasive parameters that are readily available to the clin-
ician. Predicted and observed risks were concordant both in the
overall population and in key patient subgroups. In addition, the
model compared favourably to a clinically available treatment algo-
rithm, suggesting greater utility in everyday clinical practice.
Prior studies
This work builds upon numerous efforts in the ARVC community
directed towards optimization of arrhythmic risk stratification.
Indeed, selection of pre-specified predictors was based on a meta-
analysis that included 45 studies examining the association of clinical
and demographic characteristics with VAs.5 Despite this wealth of
data, a lack of systematically analysed results complicates their trans-
lation to clinical care. Interpretation of the results of prior studies has
been significantly hampered by limited sample sizes and heteroge-
neous study populations.5 In addition, none of the prior studies were
designed to derive a prediction model that can be applied to clinical
care. The 2015 ITFC Statement for Treatment of ARVC was a major
step forward in consolidating the literature and proposing an
Figure 3 Outcomes of patients associated with model-based implantable cardioverter-defibrillator implantation thresholds. The implications of
implanting an implantable cardioverter-defibrillator in all (left bar) or none (second-to-right bar) of the patients are shown, as well as the implications
of treating all patients as per International Task Force Consensus Statement (far right bar). The rest of the bars show the impact of using different
implantable cardioverter-defibrillator placement thresholds based on the risk calculated by our model. Each bar represents the complete cohort
(n= 528) and colour coding represents the proportion of patients experiencing sustained ventricular arrhythmia (red) or absence thereof (blue) as
well as the placement (solid colours) vs. the non-placement (striped colours) of an implantable cardioverter-defibrillator. The black triangles repre-
sent the number of implantable cardioverter-defibrillators needed to protect one patient developing ventricular arrhythmia, with a horizontal dotted
line for the reference value (i.e. treatment as per International Task Force Consensus Statement). Left y axis denotes proportion of patients (corre-
sponding to the colour coding); right y axis denotes the number of implantable cardioverter-defibrillators needed to protect one patient (corre-
sponding to the black triangles). ICD, implantable cardioverter-defibrillator; ICD:VA, ratio of implantable cardioverter-defibrillator placements
required to protect one patient developing ventricular arrhythmia; ITFC, International Task Force Consensus Statement.
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algorithm for ICD placement.1 Nevertheless, the ITFC recommenda-
tions were based on expert opinion and provided only risk strata
with a crude estimate of risk. Opportunities for improvement were
subsequently raised.8 Therefore, to the present day, there is no uni-
formly accepted risk stratification algorithm for ARVC.
Model development and validation
In order to be widely applicable, a risk stratification algorithm should
be derived from a broad population, simple, and easy to use. As such,
we assembled the largest cohort to date of ARVC patients from
multinational transatlantic registries, and measured seven easily avail-
able clinical parameters. Our model showed good discrimination be-
tween those with vs. without sustained VA (as indicated by the
C-statistic), and good agreement between observed and predicted
sustained VA risk (as determined by the calibration plots). In addition,
sensitivity analyses revealed that the relationships between predic-
tors and outcome were comparable in key patient subgroups.
The need for accurate ventricular
arrhythmia risk prediction in
arrhythmogenic right ventricular
dysplasia/cardiomyopathy
Our study quantifies the high rate of VA events in ARVC patients
without a pre-existing history of sustained VA (5.6% per year). While
this event rate is significantly higher than for other types of non-
ischaemic cardiomyopathies, it is comparable to previous studies in
primary prevention ARVC populations, which reported annual event
rates of 2–10%.2,16 Faced with this high event rate, many clinicians
would agree that the majority of patients with definite ARVC benefit
from ICD placement. However, ICD placement has significant draw-
backs in this usually young and active population, including a consider-
able risk of complications and inappropriate interventions.17
Appropriate patient selection is thus of paramount importance.
Clinical utility
The greatest clinical utility of our model lies in the accurate individual-
ized quantification of arrhythmic risk (Take home figure). By treating
VA risk as a continuum instead of dividing patients into high-, inter-
mediate-, and low-risk strata, we provide prognostic information that
can aid clinical decision-making for prophylactic ICD placement.
Importantly in this high-risk population, our model can help the clin-
ician identify those who would fare well without an ICD. Of note,
our study does not aim to prescribe ICD placement for a given pa-
tient. Instead, we seek to provide the clinician and patient with the
necessary data to facilitate well-informed shared clinical decision-
making.
While the acceptable risk threshold is undefined, our model per-
formed better than the current consensus-based algorithm at any
risk threshold. Importantly, our model results in a 20.6% reduction of
ICD placement compared to the ITFC consensus algorithm, while
protecting as many patients with VA events. Therefore, we believe
that the model has the potential to set the standard for everyday clin-
ical decision-making for primary prevention ICDs in patients
with ARVC. To facilitate this, we have made our model available on-
line as a ‘risk calculator’ on www.arvcrisk.com. Such a tool has had
considerable clinical utility for arrhythmic risk prediction in hyper-
trophic cardiomyopathy.18,19 It is important to recognize that ARVC
is a progressive condition. Thus, patients should be periodically re-
stratified with right ventricular function assessment, ECG, and heart
rhythm monitoring every 1–2 years as suggested in a recent expert
consensus document.1 We provided risk estimates to facilitate
shorter-term prediction and calibration plots establishing concord-
ance between predicted and observed events over these shorter
timeframes (Supplementary material online, Table S7 and Figure S1).
Limitations and future directions
Our study population was drawn from academic centres across
Northern Europe and North America. Consistent with this, patients
were predominantly Caucasian and pathogenic variants were primar-
ily identified in PKP2. Results should consequently be extrapolated
with caution to patients of other ethnic background or genotypes.
Our ascertainment from tertiary care settings may have created a re-
ferral bias that could lead to overestimation of VA risk in a
community-derived population. These limitations highlight the im-
portance of external validation studies that include patients from
community settings and with a diversity of ethnic backgrounds and
genotypes. As in similar studies, we used a surrogate composite end-
point that included appropriate ICD therapy to infer risk of SCD.
While most clinicians agree that ICD-treated VA represents a severe
event, ICD therapies are an imperfect substitute for SCD.20 To ad-
dress these limitations, we stratified the population by prophylactic
Figure 4 Decision curve analysis comparing the clinical utility of
our model (red dotted line) to the International Task Force
Consensus Statement algorithm (blue dotted line). The clinical util-
ity of both treatment strategies is compared by plotting the net
benefit (y axis) for a range of potential implantable cardioverter-de-
fibrillator placement thresholds based on the 5-year risk of VA
(x axis). Our model showed the highest net benefit for all
potential thresholds (ranging from 2.5% to 27.5%). This indicates
that our model would result in the highest weighted balance of ap-
propriate vs. inappropriate implantable cardioverter-defibrillator
placements, regardless of the clinically preferred risk threshold.
ICD, implantable cardioverter-defibrillator; ITFC, International Task
Force Consensus Statement.
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ICD placement and demonstrated the model performed similarly well
(Supplementary material online, Figure S2). There is certainly room for
further iterations of the model by including other predictors. One of
them is inducibility on programmed ventricular stimulation (PVS). The
characteristics of the 214 (40.7%) patients who underwent PVS in our
cohort with regards to the presence or absence of inducibility is pre-
sented in Supplementary material online, Table S10.
Conclusion
Based on the largest cohort to date of ARVC patients with no sus-
tained VA history at diagnosis, we present a new prediction model to
generate individualized estimates of the risk of incident VA. This
model, based on readily available clinical parameters, performs better
than the current consensus guideline and has the potential to set the
standard for prophylactic ICD placement in ARVC.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Take home ﬁgure Prediction of sustained ventricular arrhythmia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. ARVC,
arrhythmogenic right ventricular dysplasia/cardiomyopathy; inv., inversion; PVC, premature ventricular complex; RVEF, right ventricular ejection frac-
tion; VT, ventricular tachycardia.
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